Autonomix Medical appoints former Medtronic Chief Regulatory Counsel Sandra Kalter to board

Autonomix Medical, Inc.

Board expanded from five to six members; Kalter appointed independent director effective Sept 14, 2026.
Kalter spent 20 years at Medtronic, including VP and Chief Regulatory Counsel; oversaw due diligence for 27+ acquisitions.
Her Medtronic work covered Symplicity Spyral renal denervation, Evolut TAVR, Micra TPS, and PulseSelect PFA systems.
She receives standard non-employee director compensation; no committee assignments or disclosed conflicts reported.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sandra Kalter

Independent Director

AMIX · Autonomix Medical, Inc.

Effective: 2026-09-14
Filed: September 16, 2026, 8:35 AM ET

On September 14, 2026, Autonomix Medical, Inc. (the “Company”) Board of Directors (the “Board”) increased the size of the Board from five to six members and appointed Sandra Kalter as an independent member of the Company’s Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sandra Kalter was appointed as Independent Director at Autonomix Medical, Inc..

Action: appointed
Role: Independent Director

Exact text from the filing

On September 14, 2026, Autonomix Medical, Inc. (the “Company”) Board of Directors (the “Board”) increased the size of the Board from five to six members and appointed Sandra Kalter as an independent member of the Company’s Board, effective immediately.

View on SEC.gov

Autonomix Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-030505

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.